Stoke Therapeutics (STOK) Cash from Investing Activities Growth (3y) (2021 - 2026)
Stoke Therapeutics (STOK) Cash from Investing Activities Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -29.84% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 38.24% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -22.09% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Stoke Therapeutics | 1.86 Bn | 1.52 Bn | - | -1.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.52% |
| Dec 31, 2025 | -67.69% |
| Sep 30, 2025 | -48.68% |
| Jun 30, 2025 | -906.28% |
| Mar 31, 2025 | 28.07% |
| Dec 31, 2024 | -58.90% |
| Sep 30, 2024 | -78.63% |
| Jun 30, 2024 | -2.18% |
| Mar 31, 2024 | 270.75% |
| Dec 31, 2023 | 449.72% |
| Sep 30, 2023 | 283.36% |
| Jun 30, 2023 | 563.27% |
| Mar 31, 2023 | 346.52% |
| Dec 31, 2022 | 246.29% |
| Sep 30, 2022 | 389.62% |
| Jun 30, 2022 | 33.37% |
| Mar 31, 2022 | -1,046.92% |
| Dec 31, 2021 | 424.31% |
| Sep 30, 2021 | -116.88% |